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Purpose: To investigate the expression of cyclooxygenase-2 (COX-2) in a group of 93 Ecuadorian primary pterygia and
to evaluate a possible association between COX-2 and survivin.
Methods: Primary pterygium samples were treated for the immunohistochemical evaluation of COX-2 and survivin.
Mouse monoclonal antibody to COX-2 and rabbit polyclonal antibody to survivin were used. Statistical analysis was
performed using the SPSS statistical software package, version 15.0.
Results: In our study, 63 (67.7%) primary pterygia samples were positive for COX-2 staining, and 70 (75.3%) specimens
were positive for survivin expression. In the group of pterygia with survivin immunostaining, there were 55 (78.6%)
samples with COX-2 expression. The staining of both COX-2 and survivin was localized in the lower and middle layers
of the epithelium. When analyzed by Fisher's exact test, the expression of COX-2 showed a strong significant correlation
with survivin (p=0.0002).
Conclusions: These data, showing a significant correlation between COX-2 and survivin in primary pterygium, suggest
that pterygium may originate through an anti-apoptotic mechanism.
Pterygium is a common conjunctival disorder exhibiting
degenerative and hyperplastic changes as well as proliferative,
inflammatory  features  and  a  rich  vasculature.  Although
extracellular  matrix  remodeling  [1],  inflammatory  process
[2,3], anti-apoptotic mechanisms [4,5], cytokines [6], growth
and angiogenic factors [7,8], and viral infection [9,10] have
been proposed as causative agents in its pathogenesis, several
investigators  consider  pterygium  an  ultraviolet  radiation
(UV)-related  disease  [11-16].  Pterygium  has  long  been
considered  as  a  chronic  degenerative  condition;  however,
because of the finding of abnormal expression of p53 protein
in the epithelium [17-21], pterygium has been considered an
UV-related  tumor  rather  than  a  degenerative  disease.  To
support this hypothesis, we reported in a previous study the
presence of conjunctival melanocytic pigmented lesions in
pterygium and, among these, two primary acquired melanosis
with atypia [22].
UV irradiation has a key role in the formation of reactive
oxygen  species  (ROS),  short-lived  entities  continuously
generated at low levels during the course of normal aerobic
metabolism, which have been associated with inflammation,
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initiation, and progression of tumors through activation of
carcinogens [23]. ROS can induce cyclooxygenase 2 (COX-2)
production [24]. COXs are rate-limiting enzymes involved in
prostanoid  synthesis,  which  convert  arachidonic  acid  into
prostaglandin (PG) H2, a substrate for specific prostaglandin
synthases [25]. Two isoforms of COX, encoded by separate
genes,  have  been  isolated,  cloned,  and  sequenced.  The
isoform  designated  as  COX-1,  constitutively  expressed  in
most  cells  and  tissues,  modulates  normal  physiologic
responses  such  as  regulation  of  renal  and  vascular
homeostasis and gastroprotection. The other one, designed as
COX-2,  is  rapidly  induced  by  growth  factors,  cytokines,
hormones, hypoxia, bacterial endotoxins, tumor promoters,
and UV light, and its protein is frequently undetectable at
baseline in most normal adult tissues. Both ROS and COX-2
play  an  important  role  in  UV-related  cutaneous
carcinogenesis [26]. Subbaramaiah et al. [27] reported that
COX-2 expression is suppressed by normal p53, suggesting
that loss of p53 function may result in the induction of COX-2
expression.  Consistent  overexpression  of  COX-2  was
observed in a broad range of premalignant, malignant, and
metastatic human epithelial cancers [28].
Aziz  and  co-authors  [29]  demonstrated  that  UV-B
exposure  leads  to  a  significant  activation  of  survivin,  a
member of the inhibitor of apoptosis protein family (IAPs)
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458that  is  overexpressed  in  most  human  malignancies  and
implicated in the cellular stress response. It is well known that
the functional loss of wild-type p53 is associated with the
upregulation of survivin expression in several types of tumors.
Recently, we have demonstrated in pterygium a significant
association between survivin expression and oxidative stress
and p53, and we have hypothesized a UV-related loss of
normal p53 functionality [5].
Since several studies demonstrated a correlation between
COX-2 and survivin expression in tumors [30-32], the aim of
the present study was to investigate the expression of COX-2
in  a  group  of  93  Ecuadorian  primary  pterygia  by
immunohistochemistry and to evaluate a possible association
between COX-2 and survivin.
METHODS
Patients and study design: This study was based on an analysis
of  formalin-fixed,  paraffin  embedded  primary  pterygia
harvested from 93 patients (36 males and 57 females) in a
cluster of 111 people that underwent excision by bare sclera
technique at the Department of Pathology at the Cancer Center
of SOLCA (Cuenca, Ecuador) from July 2004 to December
2007.  The  selected  patients  were  of  mixed  race,  between
American Indian and Hispanic. Ages ranged between 18 and
77 years (mean age 43.35±13.9). Thirty-five patients lived in
the countryside and 58 in an urban setting. All the selected
patients  were  outdoor  workers.  Most  of  the  lesions  were
located  on  the  nasal  side  and  only  the  head  of  primary
pterygium  was  used  as  the  pterygium  sample.  Pterygium
morphology  was  clinically  graded  as  atrophic  (24  cases),
intermediate (53 cases), or fleshy (17 cases) according to an
assessment of pterygium translucency. Normal conjunctiva
samples  as  controls  were  collected  from  medial  bulbar
conjunctiva  of  10  patients  (six  males  and  four  females)
without pterygium and pinguecula who underwent cataract
surgery. Ages ranged between 25 and 70 years (mean age
52.1±16.02). The younger patients were surgically treated for
traumatic cataract. Seven patients lived in the countryside and
three resided in an urban setting. Relevant clinical features of
the  patients  are  summarized  in  Table  1.  Patients  did  not
receive any medication before surgery except for a topical
anesthetic, and no drugs or chemical agents were used during
surgical operation. The study protocol was approved by the
local research ethic committee, and informed consent was
obtained from all subjects according to the World Medical
Association Declaration of Helsinki. Complete information
on patients was available in all cases.
Immunohistochemistry: Microtome histological sections (6–
7  μm  thick)  were  treated  for  the  immunohistochemical
demonstration of COX-2 and survivin using the streptavidin-
biotin alkaline phosphatase method. They were dewaxed in
xylene  and  rehydrated  in  a  graded  alcohol  series  and
phosphate-buffered saline (PBS). Water-bath, heating-based
antigen retrieval was performed by immersion in 10 mM
citrate buffer solution (pH 6.0) at 95 °C for 40 min. After
gradual cooling for 20 min, sections were treated for 45 min
with 10% normal goat or normal horse serum in PBS. Mouse
monoclonal  antibody  (1:100,  clone  4H12;  Novocastra,
Newcastle upon Tyne, UK) to human COX-2 raised against
amino acids 30–163 of the NH2-terminus of human COX-2
molecule  and  rabbit  polyclonal  antibody  (1:1000;  Novus
Biologicals, Littleton, CO) to recombinant human survivin
protein, which recognizes the full-length recombinant human
survivin, were used as primary antisera and incubated for 60
min at room temperature while biotinylated anti-mouse and
anti-rabbit  IgG  were  used  as  secondary  antisera  (1:200;
Vector Laboratories, Burlingame, CA) and incubated for 30
min at room temperature. The sections were further incubated
in  alkaline  phosphatase  streptavidin  (1:1000;  Vector
Laboratories) for 30 min at room temperature and reacted with
Fast Red Substrate System (Dako, Glostrup, Denmark). All
sections were thoroughly rinsed in PBS between each step,
and  finally  counterstained  with  Mayer  hematoxylin  and
mounted in glycerol gelatin (Sigma, St. Louis, MO).
Sections of Crohn’s disease were used as positive control
tissue  for  COX-2,  while  sections  of  human  cutaneous
malignant  melanoma  were  used  as  positive  control  for
TABLE 1. CLINICAL FEATURES OF THE PATIENTS.
Samples Variables
Number of
patients
Pterygium
Gender
Male 36
Female 57
Age
≤ 43* 47
> 43* 46
Residency
Urban 58
Rural 35
COX-2 expression
Positive 63
Negative 30
Survivin expression
Positive 70
Negative 23
Conjunctiva
Gender
Male 6
Female 4
Age
< 55* 5
≥55* 5
Residency
Urban 3
Rural 7
This  table  presents  clinical  variables  of  the  study’s
participants and  the  immunohistochemical  analysis.  The
asterisk indicates the median value.
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459survivin. Negative controls were obtained by omission of the
primary antibody or by replacing the primary antibody with
an isotype-matched antibody. Positive and negative controls
were run simultaneously.
Micrographs were captured by a digital camera Canon
PowerShot  A620,  (Canon  Inc.,  Tokyo,  Japan)  on  a
microscope  Zeiss  Axiophot  (Carl  Zeiss  Inc.,  Oberkochen,
Germany), and processed by Adobe Photoshop (version 7.0;
Adobe Systems, Inc., San Jose, CA) software.
Evaluation of immunoreactivity: Results were independently
evaluated by three observers in a blinded fashion. Four to six
200X fields covering almost the whole of each of the four
sections per sample were examined with a 144-intersection
point square reticulum (0.78 mm2) inserted in the eyepiece and
scored for the percentage of epithelial immunoreactive cells.
Figure 1. Immunohistochemical staining for COX-2 and survivin in
adjacent  sections  of  primary  pterygium.  The  expression  of  both
COX-2 (A) and survivin (B) was localized in the lower and middle
layers of the epithelium. The immunoreactivity for survivin was
localized to the nuclei and cytoplasm, while COX-2 expression was
limited to cytoplasm. Note in A, COX-2-immunoreactive endothelial
cells in the lamina propria. Each section was counterstained with
hematoxylin. Original magnification; 400X.
The cutoff level for immunohistochemical analysis was set at
10%, meaning that those samples with more than 10% of cells
stained were considered to be positive. Patients were divided
into four groups, COX-2-positive, COX-2-negative, survivin-
positive, and survivin-negative.
Statistics: The results were assessed with Fisher’s exact test.
Data were computed by the SPSS statistical software package,
version 15.0 (SPSS Inc., Chicago, IL). A p value of less than
0.05 was considered statistically significant.
RESULTS
COX-2 expression: In our study, 63 (63/93, 67.7%) primary
pterygia  samples  were  positive  for  COX-2  staining.  The
staining was detectable in the cytoplasm of cells localized to
the  basal  and  middle  layers  of  the  epithelium  and  in  the
endothelial  cells  of  microvessels  (Figure  1A).  No
immunostaining  for  COX-2  in  normal  conjunctiva  was
present (Figure 2E). Positive control section from Crohn’s
disease  demonstrated  immunoreactivity  for  COX-2  in  the
cytoplasm of both epithelial cells located in the crypts, surface
epithelial cells, and mononuclear cells of the lamina propria
(Figure  2A).  No  staining  was  detected  when  the  primary
antibody was omitted (Figure 2B) or when an isotype control
antibody was applied.
Survivin  expression:  Positive  staining  was  detected  in  70
(70/93, 75.3%) primary pterygia. The immunoreactivity was
localized to the nuclei and cytoplasm of the epithelial cells
(Figure  1B).  No  substantial  staining  was  visible  in  the
subepithelial  fibrovascular  layers.  No  immunostaining  for
survivin in normal conjunctiva was detectable (Figure 2F).
The positive control section from human cutaneous melanoma
demonstrated immunoreactivity for survivin in the nuclei and
cytoplasm of tumoral cells (Figure 2C). Reactivity was absent
in  sections  incubated  without  primary  antibody,  and  no
reactivity developed when the isotype control antibody was
used (Figure 2D).
Relationship between COX-2 and survivin: The relationship
between COX-2 and survivin is shown in Table 2. In the group
of  pterygia  positive  to  survivin,  55/70  (78.6%)  samples
showed COX-2 expression. When analyzed by Fisher's exact
test,  the  expression  of  total  survivin  showed  a  strong
significant correlation with COX-2 (p=0.0002).
DISCUSSION
UV light is one of the most important factors involved in the
pathogenesis of pterygium, but the mechanism by which UV
radiation induces this disease still remains unknown. Several
studies demonstrated that absorption of UV by molecules in
the cell results in the generation of ROS, which can cause
oxidative DNA damage, often in the form of 8-oxo- or 8-
hydroxy-deoxyguanosine  (8-OHdG)  adducts  [33,34].  In
keratinocytes, this DNA damage leads to an increase in p53
expression [35], which arrests the cell cycle at G1/S and drive
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460the cell through apoptosis if the damage cannot be repaired.
This  mechanism  prevents  the  accumulation  of  potentially
oncogenic DNA mutations. Therefore, chronic or multiple
UV-B exposure can lead to p53 mutation and/or allelic loss
[36,37]  or  a  UV-induced  defect  in  p53  activation  [20].
Previously, we have observed p53 overexpression in 8-OHdG
immunoreactive pterygia, providing evidence that pterygium
is a tumor-like growth disorder related to faulty apoptosis
[21].
Extensive data has validated the role of UV-B as both a
tumor  initiator  and  promoter  probably  by  its  ability  to
upregulate COX-2 expression, which converts arachidonic
acid  into  PGH2  [25].  These  products  may  act  as  tumor
promoters  in  UV-initiated  tissue  or  they  may  enhance
initiation  due  to  their  ability  to  act  as  oxidants  [38].
Subbaramaiah et al. [27] reported that normal p53 suppresses
COX-2 expression, suggesting that loss of p53 function may
TABLE 2. RELATIONSHIP BETWEEN COX-2 AND SURVIVIN.
Group of patients
Survivin
positive
Survivin
negative Total
COX-2 positive 55 8 63
COX-2 negative 15 15 30
Total 70 23 93
Shown is the relationship between COX-2 and survivin. In the
group  of pterygia with survivin immunostaining, there were
55 (55/70, 78.6%) samples with COX-2 expression. Survivin
expression  was  significantly  associated  with  COX-2
positivity (p=0.0002 assessed by Fisher’s exact test).
result  in  the  induction  of  COX-2  expression.  COX-2
stimulates  tumor  cell  proliferation  and  increases  the
invasiveness  of  malignant  cells  [39]  and  enhances
angiogenesis through the production of vascular endothelial
growth factor (VEGF). Finally, a stable overexpression of
COX-2  determines  a  dramatic  resistance  to  UV-induced
apoptosis [40].
Herein,  we  have  used  immunohistochemistry  to
demonstrate  COX-2  expression  in  67.7%  of  pterygial
specimens in the cytoplasm of keratinocytes localized in the
lower  and  middle  layers  of  the  epithelium  whereas  no
immunoreactivity was detectable in normal conjunctiva. Our
data  are  in  agreement  with  Chiang  et  al.  [12],  who  have
demonstrated COX-2 expression in primary pterygium. The
results support the causal relationship between COX-2 and
pterygium and provide molecular evidence of the effects of
UV radiation in this lesion.
Since 1979 [41], it has been proposed that pterygium
could  represent  a  precancerous  condition  of  the  mucosal
epithelium,  analogous  to  cutaneous  actinic  keratosis  for
histologic  features  [42].  Actinic  keratoses  are  dysplastic
lesions  considered  to  be  precursor  to  squamous  cell
carcinomas, which result from chronic exposure to sunlight.
Buckman and co-authors [38] demonstrated the prevalence of
COX-2  not  only  in  UV-induced  human  squamous  cell
carcinoma but also in actinic keratoses.
Aziz et al. [29] have demonstrated that UV-B exposure
leads  to  a  significant  activation  of  survivin,  a  protein
belonging to the inhibitor of apoptosis (IAP) gene family, in
human  epidermal  keratinocytes.  Survivin  is  expressed  in
Figure  2.  Immunohistochemical
staining  for  COX-2,  and  survivin  in
control sections. Sections from Crohn’s
disease  (A)  and  human  cutaneous
malignant melanoma (C) were included
as positive controls. No immunostaining
for  COX-2  (E)  and  survivin  (F)  in
normal  conjunctiva  was  observed.
Sections  incubated  without  a  primary
antibody (inset B) or with an isotype
control antibody (inset D) displayed no
immunoreactivity.  Each  section  was
counterstained  with  hematoxylin.
Original  magnification,  A:  200X;
C,E,F: 400X; insets B,D: 400X.
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461embryonic or proliferating normal adult tissues and highly
upregulated in almost all types of human malignancy [43].
Survivin  overexpression  inhibits  extrinsic  or  intrinsic
apoptotic pathways through an inhibition of caspases [44].
Previously,  we  have  demonstrated  for  the  first  time  an
upregulation  of  survivin  expression  and  a  relationship
between survivin, oxidative stress, and p53 overexpression in
primary  pterygia  [5].  We  then  hypothesized  that  the
cooperation between survivin and UV-induced functional loss
of  p53  could  be  responsible  for  aberrant  inhibition  of
apoptosis  in  pterygium.  In  the  present  study,  we  have
demonstrated  a  strong  significant  COX-2  expression  in
survivin immunoreactive epithelial cells. This is the first study
to  report  a  significant  correlation  between  COX-2
upregulation and survivin expression in primary pterygium.
Several  authors  already  reported  a  relationship  between
COX-2 and survivin expression in other kinds of malignant
lesions such as ovarian [32], breast [31], and non-small cell
lung cancer [30]. Our results are in agreement with previous
data by Erkanly et al. [45] about the positive correlation of the
two proteins not only in the endometrial carcinoma but also
in a premalignant lesion such as endometrial hyperplasia.
Overall, these data indicate that COX-2 may be involved in
pterygium growth by increasing the activation of the anti-
apoptotic  protein,  survivin.  Moreover,  the  relationship
between COX-2 and survivin suggest a potential origin of
pterygium through an anti-apoptotic mechanism and confirm
that this lesion may develop toward a neoplastic-like growth
disorder  instead  of  a  degenerative  condition  of  the
conjunctiva.  These  evidences  provide  useful  information
toward the development of novel therapeutic strategies for
pterygium involving the use of COX-2 and survivin inhibitors
alone  or  in  combination,  which  might  contribute  to  the
treatment of pterygium through the suppression of the anti-
apoptotic effect of survivin and the tumorigenic induction of
COX-2.
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